Cancer drug listing boosts baby hopes
MORE women undergoing chemotherapy have been given a better chance of having a baby post-treatment, with the Federal Government expanding the listing of an effective fertility preservation medication on the Pharmaceutical Benefits Scheme.
Goserelin, sold as Zoladex, is listed on the PBS for hormone receptor positive breast cancer. But young women with hormone receptor negative breast cancer who want access to goserelin have had to pay $330 a month. They now have access to the treatment at a cost of $38 a month.
The expanded listing on the PBS will not only benefit breast cancer patients but women undergoing alkylating chemotherapy for a range of diseases, such as sarcoma, lupus and rheumatological diseases.
One of the side effects of chemotherapy is infertility because of damage to a woman’s eggs. An Australian-led trial of more than 250 women worldwide conducted by Breast Cancer Trials showed premenopausal women who received monthly injections of goserelin were more likely to become pregnant after their breast cancer treatment.